79(top 100%)
PR articles
15.3K(top 1%)
PR citations
50(top 100%)
PR h-index
62(top 100%)
h-index
100
documents
25.5K
doc citations
2.7K
citing journals
100
times ranked

Publications

79 PR articles • 15,929 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | PR Citations
#ArticleIFPR CitationsLinks
1Induction of DEPP1 by HIF Mediates Multiple Hallmarks of Ischemic Cardiomyopathy
Circulation, 2024, 150, 770-786
25.29Citations (PDF)
2Total loss of <i>VHL</i> gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity
Proceedings of the National Academy of Sciences of the United States of America, 2024, 121,
7.68Citations (PDF)
3Toward a CRISPR-based mouse model of <i>Vhl</i> -deficient clear cell kidney cancer: Initial experience and lessons learned
Proceedings of the National Academy of Sciences of the United States of America, 2024, 121,
7.610Citations (PDF)
4Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation
Nature Cell Biology, 2023, 25, 950-962
16.953Citations (PDF)
5Sensitivity of<i>VHL</i>mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway
Proceedings of the National Academy of Sciences of the United States of America, 2022, 119,
7.627Citations (PDF)
6A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer
Clinical Cancer Research, 2022, 28, 4689-4701
6.914Citations (PDF)
7Mitochondrial remodeling and ischemic protection by G protein–coupled receptor 35 agonists
Science, 2022, 377, 621-629
36.487Citations (PDF)
8Targeting oncoproteins with a positive selection assay for protein degraders
Science Advances, 2021, 7,
11.044Citations (PDF)
9DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
Neuro-Oncology Advances, 2021, 3, i12-i13
0.91Citations (PDF)
10Belzutifan, a Potent HIF2α Inhibitor, in the Pacak–Zhuang Syndrome
New England Journal of Medicine, 2021, 385, 2059-2065
43.780Citations (PDF)
11CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Cancer Cell, 2020, 37, 37-54.e9
38.5188Citations (PDF)
122-Oxoglutarate-dependent dioxygenases in cancer
Nature Reviews Cancer, 2020, 20, 710-726
61.8193Citations (PDF)
13Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle
Cell Research, 2020, 31, 80-93
12.586Citations (PDF)
14The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis
Genes and Development, 2019, 33, 1718-1738
4.7103Citations (PDF)
15HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Science Signaling, 2019, 12,
5.574Citations (PDF)
16Peptidic degron for IMiD-induced degradation of heterologous proteins
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2539-2544
7.662Citations (PDF)
17Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Cell Metabolism, 2019, 29, 1166-1181.e6
26.2155Citations (PDF)
18EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16997-17006
7.615Citations (PDF)
19Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Cancer Discovery, 2019, 9, 230-247
25.6157Citations (PDF)
20Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
JCI Insight, 2019, 4,
5.429Citations (PDF)
21The von Hippel–Lindau Tumor Suppressor Protein
Annual Review of Cancer Biology, 2018, 2, 91-109
5.422Citations (PDF)
22Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylase
Proceedings of the National Academy of Sciences of the United States of America, 2018, 115,
7.613Citations (PDF)
23HIF2 Inhibitor Joins the Kidney Cancer Armamentarium
Journal of Clinical Oncology, 2018, 36, 908-910
21.617Citations (PDF)
24BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
Proceedings of the National Academy of Sciences of the United States of America, 2018, 115,
7.625Citations (PDF)
25Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Cell, 2018, 175, 101-116.e25
34.1328Citations (PDF)
26Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL <sup>−/−</sup> clear cell renal carcinoma
Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1027-1032
7.6144Citations (PDF)
27The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
Molecular Cell, 2017, 66, 772-779
13.4255Citations (PDF)
28Common pitfalls in preclinical cancer target validation
Nature Reviews Cancer, 2017, 17, 441-450
61.8166Citations (PDF)
29HIF activation causes synthetic lethality between the <i>VHL</i> tumor suppressor and the <i>EZH1</i> histone methyltransferase
Science Translational Medicine, 2017, 9,
12.744Citations (PDF)
30Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
Cell, 2016, 166, 126-139
34.1225Citations (PDF)
31Targeting HIF2 in Clear Cell Renal Cell Carcinoma
Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 113-121
1.654Citations (PDF)
32PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
Molecular Cell, 2016, 63, 1006-1020
13.4142Citations (PDF)
33EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
Cell, 2016, 164, 884-895
34.1126Citations (PDF)
34Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
Journal of Biological Chemistry, 2016, 291, 4256-4265
2.2279Citations (PDF)
35EglN2 associates with the <scp>NRF</scp>1‐<scp>PGC</scp>1α complex and controls mitochondrial function in breast cancer
EMBO Journal, 2015, 34, 2953-2970
7.469Citations (PDF)
36Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15372-15377
7.628Citations (PDF)
37Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11642-11647
7.654Citations (PDF)
38Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis
Cancer Research, 2014, 74, 6554-6564
0.638Citations (PDF)
39Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase
Genes and Development, 2014, 28, 1429-1444
4.7123Citations (PDF)
40Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
Cancer Cell, 2014, 26, 222-234
38.585Citations (PDF)
41A genetic mechanism for Tibetan high-altitude adaptation
Nature Genetics, 2014, 46, 951-956
26.1386Citations (PDF)
42A Comprehensive Study of the VHL-R200W Chuvash Polycythemia Mutation Reveals a Gradual Dysregulation of the Hypoxia Pathway in Oncogenesis
Blood, 2014, 124, 4020-4020
4.22Citations (PDF)
43IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia
Blood, 2014, 124, SCI-6-SCI-6
4.21Citations (PDF)
44Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents
Blood, 2014, 124, 420-420
4.20Citations (PDF)
45SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer
Cancer Cell, 2013, 24, 738-750
38.5156Citations (PDF)
46Influence of Metabolism on Epigenetics and Disease
Cell, 2013, 153, 56-69
34.1817Citations (PDF)
47What a difference a hydroxyl makes: mutant IDH, (<i>R</i>)-2-hydroxyglutarate, and cancer
Genes and Development, 2013, 27, 836-852
4.7550Citations (PDF)
48Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
Blood, 2012, 120, 3509-3509
4.21Citations (PDF)
49Genetic and Functional Studies Implicate <i>HIF1</i>α as a 14q Kidney Cancer Suppressor Gene
Cancer Discovery, 2011, 1, 222-235
25.6390Citations (PDF)
50Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking<i>Rb1</i>or<i>Men1</i>
Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13379-13386
7.6149Citations (PDF)
51Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,
Blood, 2011, 118, 3161-3161
4.21Citations (PDF)
52New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
Annals of the New York Academy of Sciences, 2010, 1210, 1-7
4.111Citations (PDF)
53Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
Cancer Cell, 2009, 16, 413-424
38.5128Citations (PDF)
54Synthetic lethality: a framework for the development of wiser cancer therapeutics
Genome Medicine, 2009, 1,
9.784Citations (PDF)
55The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
Nature Reviews Cancer, 2008, 8, 865-873
61.8665Citations (PDF)
56Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
Molecular Cell, 2008, 30, 393-402
13.43,000Citations (PDF)
57Kinase requirements in human cells: III. Altered kinase requirements in<i>VHL</i>−/− cancer cells detected in a pilot synthetic lethal screen
Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16484-16489
7.6140Citations (PDF)
58The von Hippel‐Lindau Tumor Suppressor Protein: An Update
Methods in Enzymology, 2007, , 371-383
2.142Citations (PDF)
59Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
Molecular and Cellular Biology, 2007, 27, 5381-5392
2.5107Citations (PDF)
60The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
Cell, 2007, 128, 889-900
34.1418Citations (PDF)
61pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
Molecular Cell, 2007, 28, 15-27
13.4171Citations (PDF)
62von Hippel-Lindau Disease
Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 145-173
31.4311Citations (PDF)
63Failure to prolyl hydroxylate hypoxia-inducible factor α phenocopies VHL inactivation in vivo
EMBO Journal, 2006, 25, 4650-4662
7.4229Citations (PDF)
64Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 105-110
7.6290Citations (PDF)
65The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Nature Reviews Cancer, 2005, 5, 689-698
61.81,361Citations (PDF)
66Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
Cancer Cell, 2005, 8, 155-167
38.5511Citations (PDF)
67Binding of pRB to the PHD Protein RBP2 Promotes Cellular Differentiation
Molecular Cell, 2005, 18, 623-635
13.4225Citations (PDF)
68The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
Biochemical and Biophysical Research Communications, 2005, 338, 627-638
2.1201Citations (PDF)
69PROLINE HYDROXYLATION AND GENE EXPRESSION
Annual Review of Biochemistry, 2005, 74, 115-128
17.7438Citations (PDF)
70Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
PLoS Biology, 2003, 1, e83
5.0560Citations (PDF)
71How oxygen makes its presence felt
Genes and Development, 2002, 16, 1441-1445
4.7141Citations (PDF)
72Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Cancer Cell, 2002, 1, 237-246
38.5730Citations (PDF)
73Molecular basis of the VHL hereditary cancer syndrome
Nature Reviews Cancer, 2002, 2, 673-682
61.8818Citations (PDF)
74Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity
Oncogene, 2000, 19, 5703-5711
6.721Citations (PDF)
75Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
Nature Cell Biology, 2000, 2, 423-427
16.91,507Citations (PDF)
76The p53 gene family
Oncogene, 1999, 18, 7701-7705
6.7178Citations (PDF)
77Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Science, 1999, 284, 455-461
36.4833Citations (PDF)
78Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
Nature Medicine, 1997, 3, 1145-1149
39.5162Citations (PDF)
79Tumour suppression by the human von Hippel-Lindau gene product
Nature Medicine, 1995, 1, 822-826
39.5665Citations (PDF)